Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026)

Johnson & Johnson (JNJ) posted Depreciation & Amortization (CF) of $2.0 billion for Q1 2026, little changed sequentially from $2.0 billion in Q4 2025, and up 13.09% YoY from $1.8 billion in Q1 2025.

Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends

Johnson & Johnson (JNJ) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 billion in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 13.09% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 billion (up 6.02% YoY) and the FY2025 annual result came in at $7.5 billion, up 2.23% from the prior year.
  • Depreciation & Amortization (CF) held at $2.0 billion in Q1 2026 per JNJ's latest filing, from $2.0 billion in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $2.0 billion in Q4 2025, with the low at $1.4 billion in Q1 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
  • Year-over-year, Depreciation & Amortization (CF) increased 29.52% in 2023 and dropped 7.86% in 2024.
  • Johnson & Johnson's Depreciation & Amortization (CF) stood at $1.8 billion in 2022, then climbed by 4.18% to $1.8 billion in 2023, then gained by 2.88% to $1.9 billion in 2024, then advanced by 6.07% to $2.0 billion in 2025, then decreased by 0.35% to $2.0 billion in 2026.
  • Business Quant data shows JNJ's Depreciation & Amortization (CF) at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.8 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 509.00 Mn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 2.00 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 188.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.37 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 581.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 93.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 1.61 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 204.40 Mn

Historic Data

Download Data
DateValue
Mar 29, 2026 2.00 Bn
Mar 29, 2026 2.00 Bn
Dec 28, 2025 2.01 Bn
Dec 28, 2025 2.01 Bn
Sep 28, 2025 1.78 Bn
Sep 28, 2025 1.78 Bn
Jun 29, 2025 1.94 Bn
Jun 29, 2025 1.94 Bn
Mar 30, 2025 1.77 Bn
Mar 30, 2025 1.77 Bn
Dec 29, 2024 1.90 Bn
Dec 29, 2024 1.90 Bn
Sep 29, 2024 1.85 Bn
Sep 29, 2024 1.85 Bn
Jun 30, 2024 1.78 Bn
Jun 30, 2024 1.78 Bn
Mar 31, 2024 1.82 Bn
Mar 31, 2024 1.82 Bn
Dec 31, 2023 1.84 Bn
Dec 31, 2023 1.84 Bn